Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$290.78M+661.10%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nikhil Lalwani
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 970
- Beta
- 0.47
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.59
Financials
Revenue
$290.78M+661.1%Net Income
$35.15MEBITDA
$76.18M+978.0%Free Cash Flow
$70.28M+557.3%EPS (diluted)
$1.51Shares Outstanding (diluted)
21.68M+86.3%Operating Expenses
$107.86MCash & Debt
$436.35MReturn of Capital
$7.91MRevenue by Segment (annual)
$883.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $883.37M | $78.34M | $3.50 |
| 2024 | $614.38M | $-18.52M | $-1.04 |
| 2023 | $486.82M | $18.78M | $0.95 |
| 2022 | $316.38M | $-47.90M | $-3.05 |
| 2021 | $216.14M | $-42.60M | $-3.40 |
| 2020 | $208.47M | $-22.55M | $-1.88 |
| 2019 | $206.55M | $6.09M | $0.51 |
| 2018 | $201.58M | $15.49M | $1.33 |
| 2017 | $176.84M | $-1.08M | $-0.09 |
| 2016 | $128.62M | $3.93M | $0.34 |
| 2015 | $76.32M | $15.38M | $1.34 |
| 2014 | $55.97M | $28.75M | $2.61 |
| 2013 | $30.08M | $301.0K | $-0.92 |
| 2012 | $2.30M | $-27.72M | $-7.64 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $5.74
- Implied price
- $132.02
- Return from $69.13
- 13.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $65.64 — -5.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -2.0% | -2.8% | 0.4% | 3.3% | 5.8% | 8.2% |
| 3.0% | 2.2% | 5.6% | 8.5% | 11.2% | 13.7% |
| 8.0% | 7.1% | 10.7% | 13.8% | 16.6% | 19.2% |
| 13.0% | 12.1% | 15.8% | 19.1% | 22.0% | 24.7% |
| 18.0% | 17.1% | 20.9% | 24.4% | 27.4% | 30.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+16.67%Social Signal Score
Mentions (18)
- Newsseekingalpha.com·15d ago·Positive
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao - Chief Medical Officer Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Yuchen…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
ANI Pharmaceuticals Q3 Earnings Call Highlights ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.
View source ↗ - Newszacks.com·17d ago·Positive
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
View source ↗ - Newszacks.com·40d ago·Neutral
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·40d ago·Positive
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
View source ↗ - Newszacks.com·55d ago·Neutral
Implied Volatility Surging for ANI Pharmaceuticals Stock Options Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
View source ↗ - Newsseekingalpha.com·59d ago·Neutral
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.
View source ↗ - Newsglobenewswire.com·60d ago·Negative
…he FDA Approval of Everolimus Tablets for Oral Suspension PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·80d ago·Positive
ANI Pharmaceuticals to Present at September Investor Conferences PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
View source ↗ - Newszacks.com·100d ago·Negative
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
View source ↗ - Newszacks.com·100d ago·Positive
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
View source ↗ - Newszacks.com·104d ago·Neutral
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
View source ↗
Earnings
Fri, Feb 26(in 3 months)
Consensus estimate $2.58 per share
Typical surprise +23.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$2.70 vs $2.18beat
- Fri, Aug 7$2.21 vs $2.04beat
- Fri, May 8$2.05 vs $1.28beat
- Fri, Feb 27$2.33 vs $1.99beat
- Fri, Nov 7$2.04 vs $1.74beat
- Fri, Aug 8$1.80 vs $1.38beat
Estimates and results for ANIP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANIP officers and directors.
- Bought
- —
- Sold
- $13.6m
0 trades
45 trades
- Lalwani Nikhilsold
- Lalwani Nikhilsold
- Cook Meredithsold
- Carey Stephen P.sold
- Lalwani Nikhilsold
- Cook Meredithsold
- Carey Stephen P.sold
- Lalwani Nikhilsold
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANIP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
